<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308033">
  <stage>Registered</stage>
  <submitdate>5/06/2009</submitdate>
  <approvaldate>17/06/2009</approvaldate>
  <actrnumber>ACTRN12609000475246</actrnumber>
  <trial_identification>
    <studytitle>Topical immunotherapy with diphencyprone for cutaneous metastatic melanoma</studytitle>
    <scientifictitle>Response of cutaneous metastatic melanoma to topical immunotherapy with diphencyprone</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil Known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Melanoma metastatic and/or locally recurrent to skin</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Topical application of diphencyprone cream to cutaneous metastases. 

The optimal diphencyprone dose is  determined in each patient as the concentration causing adequate but not excessive contact dermatitis. The concentration may range from 0.0001% to 2%, mixed in aqueous cream. The cream is applied once per week, for 24 to 48 hours depending on intensity of response. 

If there has been no response in 3 months, the treatment will be ceased. If there is response, the treatment can be continued indefinitely until refractory disease recurrence/progression. Usually, patients will require ~1 to 3 months to achieve a response. Ongoing treatment (ie, cream applied each week at home by patients) will then be offered to any patients who request it, with the aim of preventing further recurrence.</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical clearance of cutaneous metastases (ie, active cutaneous lesions are no longer visible or palpable)</outcome>
      <timepoint>1, 3, 6, 12 and 24 months following  development of contact hypersensitivity response to diphencyprone</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Histological clearance of cutaneous metastases (S100 stain after melanin bleaching on biopsy taken from treated area)</outcome>
      <timepoint>1, 3, 6, 12 and 24 months following development of contact hypersensitivity response to diphencyprone</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Melanoma locally recurrent or metastatic to skin</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy or lactation
Severe uncontrolled eczema
Previous type I hypersensitivity to diphencyprone
Primary melanoma</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>No treatment allocation: uncontrolled study</concealment>
    <sequence>N/A</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>15/06/2009</anticipatedstartdate>
    <actualstartdate>16/06/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>4/03/2013</actualenddate>
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Prince Alfred Hospital</primarysponsorname>
    <primarysponsoraddress>Missenden Rd
Camperdown NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Prince Alfred Hospital</fundingname>
      <fundingaddress>Missenden Rd
Camperdown NSW 2050</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Other Collaborative groups</othercollaboratortype>
      <othercollaboratorname>Sydney Melanoma Unit</othercollaboratorname>
      <othercollaboratoraddress>GH3, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective is to investigate whether diphencyprone (DPCP), a chemical which can cause contact allergy on the skin in about 95% of people, can stimulate the immune system to destroy these melanoma cells. DPCP is frequently used in dermatology as a treatment for autoimmune hair loss (alopecia areata) and warts, where it also stimulates an immune attack on the wart virus. As melanoma is a tumour which is known to be particularly susceptible to immune attack, it is hoped that DPCP treatment will be helpful to patients with otherwise untreatable secondary melanoma in their skin. There have so far been a handful of published case reports of patients in whom DPCP has been helpful for melanoma.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney South West Area Health Service Ethics Committee</ethicname>
      <ethicaddress>Level 3 Building 92
Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050</ethicaddress>
      <ethicapprovaldate>9/04/2009</ethicapprovaldate>
      <hrec>09/RPAH/50</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Diona Damian</name>
      <address>Dermatology, GH3
Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050</address>
      <phone>612 9515 8295</phone>
      <fax>612 9565 1048</fax>
      <email>diona.damian@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Diona Damian</name>
      <address>Dermatology, GH3
Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050</address>
      <phone>612 9515 8295</phone>
      <fax>612 9565 1048</fax>
      <email>diona.damian@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Diona Damian</name>
      <address>Dermatology, GH3
Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050</address>
      <phone>612 9515 8295</phone>
      <fax>612 9565 1048</fax>
      <email>diona.damian@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Diona Damian</name>
      <address>Dermatology, GH3
Royal Prince Alfred Hospital
Camperdown NSW 2050</address>
      <phone>+612 9515 8295</phone>
      <fax />
      <email>diona.damian@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>